Insider trades › Peter Kolchinsky
Peter Kolchinsky
A corporate insider: an officer, director or owner of more than 10% of a company. Insiders report their trades to the SEC on Form 4The form insiders use to report each purchase or sale of their company's stock. It is due within two business days of the trade. · Last filing Sep 14, 2026
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, list Peter Kolchinsky's open-market buys and sells across companies in the last two years, with the Form 4 links.
Using 13F.ai, how did the stocks Peter Kolchinsky bought perform after the purchase compared with the S&P 500?
Using 13F.ai, are other insiders at the same companies buying or selling at the same time as Peter Kolchinsky?
Connect your AI · Plans and the 7-day free trial (card required)
Buying and selling by quarter
Dollars bought and sold on the open market over the last two years.
Bought Sold
By trade date, using the shares and price reported for each trade. Stock grants, option exercises and shares withheld for tax are left out.
Roles
The companies where this person reports as an insider, and their position at each, most recent first.
| ARTV Artiva Biotherapeutics, Inc. | Director, 10% owner | Sep 14, 2026 |
| CLYM Climb Bio, Inc. | Director, 10% owner | Jul 1, 2026 |
| SEPN Septerna, Inc. | Director, 10% owner | Jun 30, 2026 |
| SPRY ARS Pharmaceuticals, Inc. | Director, 10% owner | Jun 26, 2026 |
| SLDB Solid Biosciences Inc. | 10% owner | Jun 24, 2026 |
| ACRV Acrivon Therapeutics, Inc. | Director, 10% owner | Jun 22, 2026 |
| VOR Vor Biopharma Inc. | Director, 10% owner | Jun 12, 2026 |
| HOWL Werewolf Therapeutics, Inc. | 10% owner | Jun 11, 2026 |
| COAG Hemab Therapeutics Holdings, Inc. | 10% owner | May 14, 2026 |
| ACET Adicet Bio, Inc. | 10% owner | Apr 13, 2026 |
| SION Sionna Therapeutics, Inc. | Director, 10% owner | Nov 24, 2025 |
| CDTX Cidara Therapeutics, Inc. | Director, 10% owner | Jun 30, 2025 |
| PEPG PepGen Inc. | Director, 10% owner | Jun 6, 2025 |
| TYRA Tyra Biosciences, Inc. | Director, 10% owner | Jun 6, 2025 |
| JBIO Jade Biosciences, Inc. | 10% owner | Apr 30, 2025 |
| ETNB 89bio, Inc. | Director, 10% owner | Feb 3, 2025 |
| JANX Janux Therapeutics, Inc. | Director, 10% owner | Oct 22, 2024 |
Roles come from the filings themselves and can change over time.
Latest open-market trades
Purchases and sales at every company, most recent filing first.
| How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss. | Filing | ||||||
|---|---|---|---|---|---|---|---|
| Jul 23, 2026 | ARTV Artiva Biotherapeutics, Inc. | Buy | 59,880 | $9.96 | $596.4K | -62.6% | Form 4 ↗ |
| Jul 22, 2026 | ARTV Artiva Biotherapeutics, Inc. | Buy | 84,124 | $9.93 | $835.4K | -60.9% | Form 4 ↗ |
| Jul 21, 2026 | ARTV Artiva Biotherapeutics, Inc. | Buy | 120,582 | $9.55 | $1.2M | -60.7% | Form 4 ↗ |
| Jun 16, 2026 | ARTV Artiva Biotherapeutics, Inc. | Buy | 124,893 | $8.89 | $1.1M | -55.5% | Form 4 ↗ |
| Jun 15, 2026 | ARTV Artiva Biotherapeutics, Inc. | Buy | 15,414 | $8.99 | $138.6K | -56.3% | Form 4 ↗ |
| Jun 12, 2026 | ARTV Artiva Biotherapeutics, Inc. | Buy | 391,019 | $8.57 | $3.4M | -54.7% | Form 4 ↗ |
| Jun 11, 2026 | HOWL Werewolf Therapeutics, Inc. | Sale | 245,066 | $0.38 | $93.1K | +146.4% | Form 4 ↗ |
| Jun 11, 2026 | HOWL Werewolf Therapeutics, Inc. | Sale | 17,437 | $0.38 | $6,626 | +146.4% | Form 4 ↗ |
| Jun 10, 2026 | HOWL Werewolf Therapeutics, Inc. | Sale | 42,872 | $0.37 | $15.9K | +164.6% | Form 4 ↗ |
| Jun 10, 2026 | HOWL Werewolf Therapeutics, Inc. | Sale | 3,051 | $0.37 | $1,129 | +164.6% | Form 4 ↗ |
| Jun 9, 2026 | HOWL Werewolf Therapeutics, Inc. | Sale | 345,235 | $0.37 | $127.7K | +159.4% | Form 4 ↗ |
| Jun 9, 2026 | HOWL Werewolf Therapeutics, Inc. | Sale | 24,565 | $0.37 | $9,089 | +159.4% | Form 4 ↗ |
| May 12, 2026 | COAG Hemab Therapeutics Holdings, Inc. | Buy | 6,387 | $24.90 | $159.0K | +55.6% | Form 4 ↗ |
| Apr 6, 2026 | VOR Vor Biopharma Inc. | Sale | 44,728 | $17.31 | $774.2K | +4.9% | Form 4 ↗ |
| Apr 6, 2026 | VOR Vor Biopharma Inc. | Sale | 537,754 | $16.51 | $8.9M | +4.9% | Form 4 ↗ |
| Apr 6, 2026 | VOR Vor Biopharma Inc. | Sale | 6,775 | $18.50 | $125.3K | +4.9% | Form 4 ↗ |
| Apr 2, 2026 | VOR Vor Biopharma Inc. | Sale | 258,475 | $18.23 | $4.7M | -7.4% | Form 4 ↗ |
| Apr 2, 2026 | VOR Vor Biopharma Inc. | Sale | 1,525 | $19.06 | $29.1K | -7.4% | Form 4 ↗ |
| Dec 12, 2025 | CLYM Climb Bio, Inc. | Buy | 101,462 | $2.86 | $290.2K | +234.7% | Form 4 ↗ |
| Dec 11, 2025 | CLYM Climb Bio, Inc. | Buy | 213,099 | $2.18 | $464.6K | +341.0% | Form 4 ↗ |
| Nov 21, 2025 | SION Sionna Therapeutics, Inc. | Sale | 6,440 | $39.50 | $254.4K | -106.8% | Form 4 ↗ |
| Nov 21, 2025 | SION Sionna Therapeutics, Inc. | Sale | 7,609 | $39.50 | $300.6K | -106.8% | Form 4 ↗ |
| Nov 21, 2025 | SION Sionna Therapeutics, Inc. | Sale | 1,210 | $39.50 | $47.8K | -106.8% | Form 4 ↗ |
| Nov 21, 2025 | SION Sionna Therapeutics, Inc. | Sale | 9,924 | $39.50 | $392.0K | -106.8% | Form 4 ↗ |
| Nov 20, 2025 | SION Sionna Therapeutics, Inc. | Sale | 96 | $40.50 | $3,888 | -107.1% | Form 4 ↗ |
| Nov 20, 2025 | SION Sionna Therapeutics, Inc. | Sale | 788 | $40.50 | $31.9K | -107.1% | Form 4 ↗ |
| Nov 20, 2025 | SION Sionna Therapeutics, Inc. | Sale | 512 | $40.50 | $20.7K | -107.1% | Form 4 ↗ |
| Nov 20, 2025 | SION Sionna Therapeutics, Inc. | Sale | 604 | $40.50 | $24.5K | -107.1% | Form 4 ↗ |
| Nov 20, 2025 | SION Sionna Therapeutics, Inc. | Sale | 1,235 | $39.89 | $49.3K | -107.1% | Form 4 ↗ |
| Nov 20, 2025 | SION Sionna Therapeutics, Inc. | Sale | 150 | $39.89 | $5,984 | -107.1% | Form 4 ↗ |
| Nov 20, 2025 | SION Sionna Therapeutics, Inc. | Sale | 801 | $39.89 | $32.0K | -107.1% | Form 4 ↗ |
| Nov 20, 2025 | SION Sionna Therapeutics, Inc. | Sale | 947 | $39.89 | $37.8K | -107.1% | Form 4 ↗ |
| Oct 30, 2025 | VOR Vor Biopharma Inc. | Sale | 24,579 | $25.12 | $617.4K | -33.3% | Form 4 ↗ |
| Oct 29, 2025 | VOR Vor Biopharma Inc. | Sale | 251,518 | $25.22 | $6.3M | -33.6% | Form 4 ↗ |
| Oct 28, 2025 | VOR Vor Biopharma Inc. | Sale | 87,828 | $27.10 | $2.4M | -37.7% | Form 4 ↗ |
| Oct 28, 2025 | VOR Vor Biopharma Inc. | Sale | 36,483 | $28.18 | $1.0M | -37.7% | Form 4 ↗ |
| Jun 26, 2025 | CDTX Cidara Therapeutics, Inc. | Buy | 2.27M | $44.00 | $100.0M | +348.2% | Form 4 ↗ |
| Jun 5, 2025 | TYRA Tyra Biosciences, Inc. | Buy | 213,334 | $10.04 | $2.1M | +69.7% | Form 4 ↗ |
| Jun 4, 2025 | TYRA Tyra Biosciences, Inc. | Buy | 997,864 | $9.63 | $9.6M | +68.6% | Form 4 ↗ |
| Jan 30, 2025 | ETNB 89bio, Inc. | Buy | 5.71M | $8.75 | $50.0M | +41.6% | Form 4 ↗ |
| Oct 18, 2024 | JANX Janux Therapeutics, Inc. | Buy | 1.20M | $44.75 | $53.7M | -106.3% | Form 4 ↗ |
Each row links to its Form 4. Since trade compares the stock’s move from the close on the trade date (or the next trading day) to its latest close with the S&P 500 over the same days, adjusted for splits and excluding dividends. It describes the stock, not what the trader made: we don’t know their purchase price, position size or later sales. A dash means the trade isn’t matched to a listed stock, or there is no closing price after it yet.
When several people report on the same filing, we list it under the first one named, so trades by someone usually listed second may be missing here. Information, not investment advice: see the disclaimer.